\-\ Texto\\:\\ \ \(0\)\
\-\ pe\\:\\ \\ pelvic\\ mass\\ \\ \\(especially\\ on\\ bimanual\\ under\\ anesthesia\\)\\	\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \ \(34\)\
\-\ lab\\:\\ ua\\ \\-\\ gross\\ hematuria\\,\\ malignant\\ cytology\ \(0\)\
\-\ superficial\\ \\(carcinoma\\ in\\ situ\\)\\:\ \(0\)\
\-\ endoscopic\\ resection\\ with\\ f\\/u\\ q3\\-6\\ mos\ \(0\)\
\-\ recurrence\\:\\ laser\\ therapy\\ or\\ intravesical\\ thiotepa\\,\\ doxorubicin\\,\\ mitomycin\\,\\ or\\ bcg\\.\ \(0\)\
\-\ invasive\\ \\(extension\\ into\\ muscle\\ or\\ perivesical\\ fat\\)\\:\\ \ \(0\)\
\-\ cystectomy\ \(93\)\
\-\ radiation\\ treatment\ \(15\)\
\-\ metastatic\\ \\(grim\\ prognosis\\)\\:\ \(0\)\
\-\ chemotherapy\\:\\ cisplatin\\,\\ methotrexate\\,\\ doxorubicin\\,\\ cyclophosphomide\\,\\ vinblastine\ \(0\)\
\-\ kub\\:\\ \\ punctate\\,\\ coarse\\ linear\\ calcifications\\ encrusted\\ on\\ surface\\ or\\ within\\ tumor\\ located\\ in\\ the\\ bladder\\ region\\ suggests\\ malignancy\\.\ \(0\)\
\-\ carcinoma\\ of\\ the\\ bladder\ \(2\)\
\-\ 73yo\\ african\\ american\\ male\\ with\\ gross\\ hematuria\\,\\ otherwise\\ asymptomatic\ \(0\)\
\-\ demographics\\:\\ men\\ 3x\\'s\\ \\>\\ women\ \(0\)\
\-\ 60\\-70\\ years\\ old\ \(1\)\
\-\ associated\\ with\\ the\\ following\\:\ \(0\)\
\-\ 1\\.\\)\\ exposure\\ to\\ aromatic\\ amines\ \(0\)\
\-\ \\(2\\-naphthylamine\\)\ \(1\)\
\-\ dye\\,\\ chemical\\,\\ rubber\\ industries\ \(1\)\
\-\ 2\\.\\)\\ \\ smokers\ \(0\)\
\-\ 3\\.\\)\\ \\ recurrent\\ nephrolithiasis\ \(0\)\
\-\ 4\\.\\)\\ \\ recurrent\\ uti\\'s\ \(0\)\
\-\ 5\\.\\)\\ \\ travel\\/residence\\ in\\ middle\\ east\ \(0\)\
\-\ chronic\\ schistosomial\\ infections\ \(1\)\
\-\ present\\ with\\ the\\ following\\ symptoms\\:\ \(0\)\
\-\ 1\\.\\)\\ gross\\ hematuria\\ \\(75\\%\\ of\\ patients\\)\\ dysuria\ \(0\)\
\-\ 2\\.\\)\\ frequency\ \(0\)\
\-\ 3\\.\\)\\ urgency\\ \\(25\\%\\ of\\ patients\\)\ \(0\)\
\-\ 4\\.\\)\\ pelvic\\ and\\/or\\ flank\\ pain\ \(0\)\
\-\ 5\\.\\)\\ visceral\\ or\\ osseous\\ pain\\ from\\ metastasis\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ \\:\\:\\ 0\\.05756029155508016\ \(0\)\
\-\ doxorubicin\\:\\ 0\\.05718945457732629\ \(0\)\
\-\ gross\\:\\ 0\\.05653592077226733\ \(0\)\
\-\ hematuria\\:\\ 0\\.056296451238454746\ \(0\)\
\-\ \\)\\:\\ 0\\.05615805910151012\ \(0\)\
\-\ q3\\-6\\:\\ 0\\.04081258529614119\ \(0\)\
\-\ thiotepa\\:\\ 0\\.04081258529614119\ \(0\)\
\-\ cyclophosphomide\\:\\ 0\\.04081258529614119\ \(0\)\
\-\ 73yo\\:\\ 0\\.04081258529614119\ \(0\)\
\-\ aromatic\\:\\ 0\\.04081258529614119\ \(0\)\
\-\ amines\\:\\ 0\\.04081258529614119\ \(0\)\
\-\ 2\\-naphthylamine\\:\\ 0\\.04081258529614119\ \(0\)\
\-\ industries\\:\\ 0\\.04081258529614119\ \(0\)\
\-\ uti\\'s\\:\\ 0\\.04081258529614119\ \(0\)\
\-\ travel\\/residence\\:\\ 0\\.04081258529614119\ \(0\)\
\-\ schistosomial\\:\\ 0\\.04081258529614119\ \(0\)\
\-\ intravesical\\:\\ 0\\.037603570571326635\ \(0\)\
\-\ encrusted\\:\\ 0\\.037603570571326635\ \(0\)\
\-\ rubber\\:\\ 0\\.037603570571326635\ \(0\)\
\-\ mitomycin\\:\\ 0\\.03572641729304809\ \(0\)\
\-\ perivesical\\:\\ 0\\.03572641729304809\ \(0\)\
\-\ 3x\\:\\ 0\\.03572641729304809\ \(0\)\
\-\ dye\\:\\ 0\\.03572641729304809\ \(0\)\
\-\ bcg\\:\\ 0\\.03439455584651207\ \(0\)\
\-\ grim\\:\\ 0\\.03439455584651207\ \(0\)\
\-\ east\\:\\ 0\\.03439455584651207\ \(0\)\
\-\ recurrent\\:\\ 0\\.03338918769560257\ \(0\)\
\-\ vinblastine\\:\\ 0\\.033361483849687026\ \(0\)\
\-\ cisplatin\\:\\ 0\\.03251740256823353\ \(0\)\
\-\ pelvic\\:\\ 0\\.032474543764493456\ \(0\)\
\-\ bladder\\:\\ 0\\.03211491567823175\ \(0\)\
\-\ cystectomy\\:\\ 0\\.03180374201347771\ \(0\)\
\-\ 60\\-70\\:\\ 0\\.03180374201347771\ \(0\)\
\-\ smokers\\:\\ 0\\.030640249289954992\ \(0\)\
\-\ urgency\\:\\ 0\\.028937819752337782\ \(0\)\
\-\ mos\\:\\ 0\\.028594727288663146\ \(0\)\
\-\ demographics\\:\\ 0\\.028594727288663146\ \(0\)\
\-\ bimanual\\:\\ 0\\.028275315846593922\ \(0\)\
\-\ laser\\:\\ 0\\.027976526396882945\ \(0\)\
\-\ cytology\\:\\ 0\\.026717574010384604\ \(0\)\
\-\ anesthesia\\:\\ 0\\.02629640837054328\ \(0\)\
\-\ visceral\\:\\ 0\\.02629640837054328\ \(0\)\
\-\ kub\\:\\ 0\\.025910382403232856\ \(0\)\
\-\ situ\\:\\ 0\\.02572880502752322\ \(0\)\
\-\ dysuria\\:\\ 0\\.02572880502752322\ \(0\)\
\-\ methotrexate\\:\\ 0\\.025223252749907516\ \(0\)\
\-\ f\\/u\\:\\ 0\\.024625050289351934\ \(0\)\
\-\ chemical\\:\\ 0\\.024352640567023538\ \(0\)\
\-\ \\(\\:\\ 0\\.023409870757902886\ \(0\)\
\-\ coarse\\:\\ 0\\.023399621797559885\ \(0\)\
\-\ endoscopic\\:\\ 0\\.02329318884281591\ \(0\)\
\-\ nephrolithiasis\\:\\ 0\\.02329318884281591\ \(0\)\
\-\ or\\:\\ 0\\.02318339696675249\ \(0\)\
\-\ 5\\:\\ 0\\.02314963354114966\ \(0\)\
\-\ punctate\\:\\ 0\\.023087393645728718\ \(0\)\
\-\ following\\:\\ 0\\.022456275526862482\ \(0\)\
\-\ carcinoma\\:\\ 0\\.022425256203850615\ \(0\)\
\-\ men\\:\\ 0\\.022345066562047333\ \(0\)\
\-\ 4\\:\\ 0\\.02204603615906523\ \(0\)\
\-\ superficial\\:\\ 0\\.021143625842208975\ \(0\)\
\-\ ua\\:\\ 0\\.02101320511551131\ \(0\)\
\-\ frequency\\:\\ 0\\.020886358012788556\ \(0\)\
\-\ african\\:\\ 0\\.020642637024430123\ \(0\)\
\-\ exposure\\:\\ 0\\.020583660053238317\ \(0\)\
\-\ patients\\:\\ 0\\.02047754258672246\ \(0\)\
\-\ 75\\:\\ 0\\.02024475540498232\ \(0\)\
\-\ invasive\\:\\ 0\\.019878378920914156\ \(0\)\
\-\ suggests\\:\\ 0\\.019778813156002287\ \(0\)\
\-\ lab\\:\\ 0\\.019355506646929917\ \(0\)\
\-\ women\\:\\ 0\\.019222589490066812\ \(0\)\
\-\ american\\:\\ 0\\.01884530692408911\ \(0\)\
\-\ 1\\:\\ 0\\.018827095999626915\ \(0\)\
\-\ infections\\:\\ 0\\.018805223300278395\ \(0\)\
\-\ prognosis\\:\\ 0\\.01876548374615158\ \(0\)\
\-\ flank\\:\\ 0\\.018609851288748872\ \(0\)\
\-\ 3\\:\\ 0\\.0185275511732087\ \(0\)\
\-\ \\%\\:\\ 0\\.018456676234685256\ \(0\)\
\-\ pe\\:\\ 0\\.01777215130345335\ \(0\)\
\-\ surface\\:\\ 0\\.017463394940033572\ \(0\)\
\-\ under\\:\\ 0\\.01728756508787979\ \(0\)\
\-\ recurrence\\:\\ 0\\.017258898558954232\ \(0\)\
\-\ 2\\:\\ 0\\.01703800459731987\ \(0\)\
\-\ osseous\\:\\ 0\\.01679691026910066\ \(0\)\
\-\ linear\\:\\ 0\\.0167711183938717\ \(0\)\
\-\ and\\/or\\:\\ 0\\.016719961744859735\ \(0\)\
\-\ especially\\:\\ 0\\.016283338228789173\ \(0\)\
\-\ located\\:\\ 0\\.016283338228789173\ \(0\)\
\-\ 25\\:\\ 0\\.015991788232671632\ \(0\)\
\-\ malignancy\\:\\ 0\\.015287452212044054\ \(0\)\
\-\ \\,\\:\\ 0\\.015039448084293743\ \(0\)\
\-\ metastasis\\:\\ 0\\.014809015399536697\ \(0\)\
\-\ calcifications\\:\\ 0\\.014709091456633112\ \(0\)\
\-\ middle\\:\\ 0\\.014468328563159433\ \(0\)\
\-\ malignant\\:\\ 0\\.0142994012795338\ \(0\)\
\-\ muscle\\:\\ 0\\.014209792747344189\ \(0\)\
\-\ otherwise\\:\\ 0\\.014209792747344189\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.014180304560837338\ \(0\)\
\-\ extension\\:\\ 0\\.014121885746211357\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.013373112953685588\ \(0\)\
\-\ \\>\\:\\ 0\\.013144294049391502\ \(0\)\
\-\ radiation\\:\\ 0\\.012982644673899705\ \(0\)\
\-\ resection\\:\\ 0\\.012337572479260272\ \(0\)\
\-\ fat\\:\\ 0\\.012032001494822376\ \(0\)\
\-\ years\\:\\ 0\\.011616866375085567\ \(0\)\
\-\ region\\:\\ 0\\.011174079755737558\ \(0\)\
\-\ chronic\\:\\ 0\\.011143470522717592\ \(0\)\
\-\ therapy\\:\\ 0\\.010577040723336172\ \(0\)\
\-\ metastatic\\:\\ 0\\.009958839831555972\ \(0\)\
\-\ symptoms\\:\\ 0\\.009859525356009903\ \(0\)\
\-\ pain\\:\\ 0\\.009663038588247543\ \(0\)\
\-\ into\\:\\ 0\\.009413547999813457\ \(0\)\
\-\ associated\\:\\ 0\\.009335474823646767\ \(0\)\
\-\ tumor\\:\\ 0\\.009223297692642645\ \(0\)\
\-\ present\\:\\ 0\\.00893522571264667\ \(0\)\
\-\ \\'s\\:\\ 0\\.008722438047995579\ \(0\)\
\-\ \\-\\:\\ 0\\.008480224345872053\ \(0\)\
\-\ treatment\\:\\ 0\\.00800748592407818\ \(0\)\
\-\ within\\:\\ 0\\.007546904668454081\ \(0\)\
\-\ male\\:\\ 0\\.007153729342071635\ \(0\)\
\-\ on\\:\\ 0\\.006702694558939149\ \(0\)\
\-\ from\\:\\ 0\\.0058631283016398715\ \(0\)\
\-\ in\\:\\ 0\\.00585273930750354\ \(0\)\
\-\ mass\\:\\ 0\\.00550213429142391\ \(0\)\
\-\ old\\:\\ 0\\.004050623133621549\ \(0\)\
\-\ the\\:\\ 0\\.002560171938956033\ \(0\)\
\-\ with\\:\\ 0\\.0021667440016646246\ \(0\)\
\-\ to\\:\\ 0\\.001977167168717529\ \(0\)\
\-\ \\.\\:\\ 0\\.001972196449852571\ \(0\)\
\-\ of\\:\\ 0\\.0016181083444165058\ \(0\)\
